Clinical Topics & News
Literature Review
Deep Gray Matter Volume Loss May Drive Disability Worsening in MS
Deep gray matter volume loss drives disability accumulation in multiple sclerosis (MS), according to a multicenter, longitudinal study published...
Literature Review
MRI May Reveal PML in Patients With Undetectable JCV
Patients with multiple sclerosis (MS) who are treated with natalizumab can have small progressive multifocal leukoencephalopathy (PML) lesions on...
Video
VIDEO: AAN MS guidelines aim to help clinicians weigh expanding drug choices
LOS ANGELES – A “dramatically different” landscape of treatment options allows better tailoring to patients, authors say.
News
Blood-brain barrier health may signal early loss of MS treatment response
A single dynamic contrast-enhanced MRI scan at 6 months was predictive in patients taking natalizumab or fingolimod.
News
Rare, serious alemtuzumab adverse events emerge
New reports reveal rare adverse events in the treatment of relapsing-remitting multiple sclerosis using alemtuzumab.
Literature Review
Are Complementary and Alternative Treatments Effective for MS?
Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...
News
Frankincense extract may reduce disease activity in relapsing-remitting MS
Safety results and potential efficacy point to possible future clinical development.
News
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
But the absolute difference in the rate of confirmed disability progression versus placebo was small.
News
MRI finds PML in some natalizumab-treated patients despite negative CSF, no symptoms
Correlation also observed between viral load and lesion volume.
Conference Coverage
Alemtuzumab-induced autoimmunity: getting closer to answers
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.